VIVEbiotech receives half a million euros to boost development, innovation, and research
VIVEbiotech has received financial support amounting to €547,989 for the 2015–2018 period, aimed at giving a greater boost to development, innovation, and research.
This grant, awarded by the Ministry of Economy and Competitiveness, falls within the Societal Challenges Call, which aims to support projects carried out in cooperation between companies and research organizations, with the goal of promoting new technologies, the business application of new ideas and techniques, and contributing to the creation of new products and services.
The objective is to stimulate R&D&I by creating innovative companies, steering the activity of existing companies toward innovation, mobilizing private investment, generating employment, and improving the country’s technological balance, as well as strengthening international leadership capacity by enhancing the competitiveness of the business sector.
The funding VIVEbiotech receives for the next four years is based on its technical and innovative capabilities, its socio‑economic impact, and the international projection of its project entitled “Gene Therapy 2.0: new generation of episomal viral vectors with high biosafety and their pre‑industrial development.” This project involves, among other actions, the development, validation, and production of a new generation of safer and more stable viral vectors.
The project aims to establish the scientific, clinical, and industrial capabilities necessary to develop new pre‑industrial strategies for the production of viral vectors for clinical use, to demonstrate the validity of LentiSoma for the genetic correction of a disease, and to enable VIVEbiotech to bring LentiSoma into a clinical trial phase.